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To the editor,
We read with interest the manuscript entitled “Anak-
inra treatment in critically ill COVID-19 patients: a pro-
spective cohort study” by Kooistra et  al. [1] reporting 
the potential efficacy of anakinra (ANA) to control the 
hyperinflammation in COVID-19 patients.
In our clinical practice, we adopted the early use of 
intravenous ANA for the treatment of cardiac disfunction 
in Pediatric Inflammatory Multisystem Syndrome tem-
porally associated with SARS CoV-2 infection (PIMS-TS) 
patients. During the second COVID-19 wave, 9 PIMS-TS 
children were admitted to Meyer Children’s University 
Hospital in Florence (mean age of 10.2 y [IQR] 8.5–13). 
Echocardiography revealed a left ventricular ejection 
fraction (LVEF) ≤ 40% in 5/9 patients. In these 5 chil-
dren, ANA was adopted as first-line therapy and admin-
istered as continuous intravenous infusion at 10 mg/kg/
day (400  mg/day maximum dose). Within the first day 
of ANA therapy, fractionated IVIG (2 g/kg) and intrave-
nous steroids (one methylprednisolone pulses [30 mg/kg/
day, maximum 1  g/day] in 3 consecutive days followed 
by 1  mg/kg/day intravenous methylprednisolone) were 
subsequently associated. At median time of 24 h (range 
12–36 h) from starting ANA, all patients restored LVEF 
to > 55% along with a progressive reduction of troponin 
and N-terminal pro B-type natriuretic peptide (NT pro-
BNP) values (Fig. 1). A concomitant reduction until dis-
continuation of inotropic support was obtained together 
with the recovery of clinical sings and inflammatory 
parameters.
In order to prevent the inflammatory rebound, ANA 
therapy was tapered in 2 weeks, then switched subcuta-
neously and stopped after 5 weeks (range 4–6).
One month after discharge, echocardiography reported 
stably normal findings.
The early use of ANA prompted a rapid and sub-stained 
LEVF improvement over one day from admission. Our 
results further support the assumption that an aggres-
sive, early and overtime immunomodulatory approach 
in PIMS-TS patients with myocardial involvement may 
induce a faster time to recovery, as quickly damping the 
cytokine storm [2, 3]. However, the cumulative effect of 
ANA in combination with subsequent IVIG and steroid 
use could be advocated as effective in restoring a normal 
LVEF. Due to the poor peripheral perfusion and hemo-
dynamic instability into the early phases of PIMS-TS, 
continuous intravenous infusion may be the preferable 
administration route. Subcutaneous injections might be 
considered as maintenance therapy after achieving stable 
conditions [3].
Future randomized controlled trials and long-term 
follow-up could test the hypothesis that a step-down 
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immunomodulatory approach could be preferred in 
PIMS-TS patients experiencing myocardial disfunc-
tion to avoid a further progression and/or the onset of 
sequalae over time.
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Anakinra to treat COVID‑19‑related hyperinflammation
We thank Mastrolia and colleagues for their letter in 
response to our study. They describe the use of anakinra 
in 5 pediatric patients suffering from Pediatric Inflam-
matory Multisystem Syndrome temporally associated 
with Severe Acute Respiratory Syndrome Coronavirus 2 
(SARS-CoV-2) infection (PIMS-TS) and a left ventricular 
ejection fraction (LVEF) ≤ 40%. Within 36 h, both LVEF 
and cardiac biomarkers recovered, enabling discontinua-
tion of inotropic support in all patients.
Although severe pediatric cases of SARS-CoV-2 infec-
tion are rare, children with PIMS-TS present with a com-
plex multisystem inflammatory  syndrome which often 
necessitates admission to the Intensive Care Unit (ICU). 
This syndrome is distinct from Coronavirus Disease 2019 
(COVID-19), not only in terms of clinical features, but 
also because PIMS-TS may manifest up to weeks after 
SARS-CoV-2 infection [4]. Cardiac function, as in the 5 
cases reported by Mastrolia et al., is commonly affected 
in patients presenting with PIMS-TS [5]. Furthermore, 
preclinical data have shown beneficial effects of anakinra 
in Kawasaki disease [6], which shares many features with 





























Fig. 1 Trend of mean NT pro-BNP and troponin values in relation to PIMS-TS patients’ LVEF after starting anakinra (ANA)
Fig. 2 Plasma levels of a C-reactive protein, b procalcitonin, c white blood cell counts, d ferritin, and e body temperature on day of admission 
to the intensive care unit (ICU), start of anakinra therapy, and until 8 days following cessation of anakinra. Results of 13 anakinra-treated patients 
of which data were available on multiple days after cessation of anakinra treatment are shown. Data are presented as geometric mean with 95% 
confidence intervals. Anakinra therapy was initiated 12 [7–17] and ceased 22 [18–25] days following ICU admission (median [IQR]). P-values were 
calculated using paired t-tests and mixed effect model analysis on log-transformed data. No inflammatory rebound effect was observed following 
cessation of anakinra therapy
(See figure on next page.)
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While the results presented by Mastrolia and col-
leagues are encouraging, several aspects clearly limit 
the conclusions. First, no control group receiving stand-
ard care was included. This is of relevance, as previous 
reports describe that LVEF may also recover fairly quickly 
without anakinra treatment [5]. Second, the authors used 
anakinra in combination with high-dose methylpredni-
solone and intravenous immunoglobulins. Especially the 
use of high dosages of corticosteroids impedes proper 
assessment of the effects of anakinra. Third, anakinra 
treatment was tapered over a period of 5 weeks, to pre-
vent an inflammatory rebound according to the authors. 
In our study in critically ill COVID-19 patients [1], anak-
inra treatment was not tapered. Inspired by the strategy 
of Mastrolia et al., we assessed whether cessation of anak-
inra treatment resulted in an increase in inflammatory 
parameters in our COVID-19 patients. We analyzed our 
data until 8 days after cessation of anakinra, which, given 
the half-life of 4–6  h, should reveal a rebound effect, if 
present. As depicted in Fig.  2 however, no such inflam-
matory rebound effect was observed.
Taken together, the interesting findings by Mastrolia 
and colleagues certainly warrant further study in a more 
controlled setting. Our results indicate that, in adult 
COVID-19 patients, a rebound inflammatory response 
does not occur when anakinra is stopped, indicating that 
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